ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1869

The Role of Faecal Calprotectin in IgA Vasculitis

Alojzija Hocevar1, Matija Bajzelj1, Matija Tomšič2 and Katja Lakota3, 1UKC Ljubjana, Ljubjana, Slovenia, 2Department of Rheumatology, University Medical Centre Ljubljana, Ljubljana, Slovenia, 3Department of Rheumatology, University Medical Centre Ljubljana, Llubljana, Slovenia

Meeting: ACR Convergence 2021

Keywords: IgA vasculitis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 9, 2021

Title: Vasculitis – Non-ANCA-Associated & Related Disorders Poster II (1862–1888)

Session Type: Poster Session D

Session Time: 8:30AM-10:30AM

Background/Purpose: Gastrointestinal involvement (GI) is associated with significant morbidity in acute IgA vasculitis (IgAV). Besides the abdominal pain, bowel ischemia could lead to bleeding, perforation, or ileus among others. Our aim was to investigate the role of faecal calprotectin measurement in patients with adult IgAV.

Methods: Faecal calprotectin was determined at presentation in 70 patients with histologically proven adult IgAV diagnosed at our secondary/tertiary rheumatology center. Based on the calprotectin level, patients were stratified into two groups – those with elevated vs. normal level (the cut off >50 μg/g). Clinical features of patients with elevated vs. normal faecal calprotectin were compared. Logistic regression was used to determine factors associated with elevated faecal calprotectin in IgAV.

Results: Our cohort consisted of 45 males (64.3%) and 25 females (35.7%), median (IQR) age 63.9 (45.9; 69.2) years, with median (IQR) IgAV symptom duration time 7 (4; 21) days. Seventeen patients (24.3%) had GI involvement (abdominal pain, overt GI bleeding, occult GI bleeding, diarrhoea, ileus developed in 15, 4, 12, 6 and 1 patient, respectively). Twenty-eight out of 70 patients (40.0%) had elevated faecal calprotectin, with median (IQR) level of 86.3 (64.0; 192.8) μg/g, of them 8 had clinically GI involvement. We found no significant association between clinical GI involvement and elevated faecal calprotectin (p=0.574). Characteristics of IgAV patients with elevated vs. normal faecal calprotectin are presented in Table 1. Multivariate analysis showed that elevated calprotectin was associated with increasing patient age (OR 1.04 (95%CI 1.01-1.08); p=0.018), purpura above waistline (OR 3.37 (95%CI 1.07-10.58); p=0.037) and C-reactive protein (OR 1.02 (95%CI 1.00-1.03); p=0.017

Conclusion: Our result show that the role of faecal calprotectin measurements in evaluating GI involvement adult IgAV is rather limited.

Table 1. Characteristics of IgA vasculitis patients with elevated vs. normal fecal calprotectin


Disclosures: A. Hocevar, None; M. Bajzelj, None; M. Tomšič, None; K. Lakota, None.

To cite this abstract in AMA style:

Hocevar A, Bajzelj M, Tomšič M, Lakota K. The Role of Faecal Calprotectin in IgA Vasculitis [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/the-role-of-faecal-calprotectin-in-iga-vasculitis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-role-of-faecal-calprotectin-in-iga-vasculitis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology